ATE501726T1 - Zusammensetzung mit immunogenen mikroteilchen - Google Patents

Zusammensetzung mit immunogenen mikroteilchen

Info

Publication number
ATE501726T1
ATE501726T1 AT01966829T AT01966829T ATE501726T1 AT E501726 T1 ATE501726 T1 AT E501726T1 AT 01966829 T AT01966829 T AT 01966829T AT 01966829 T AT01966829 T AT 01966829T AT E501726 T1 ATE501726 T1 AT E501726T1
Authority
AT
Austria
Prior art keywords
microparticles
composition
immunogenic microparticles
provides
immunogenic
Prior art date
Application number
AT01966829T
Other languages
English (en)
Inventor
Magdalena Plebanski
Original Assignee
Austin Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR4888A external-priority patent/AUPR488801A0/en
Priority claimed from AUPR4962A external-priority patent/AUPR496201A0/en
Application filed by Austin Research Inst filed Critical Austin Research Inst
Application granted granted Critical
Publication of ATE501726T1 publication Critical patent/ATE501726T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT01966829T 2000-09-14 2001-09-14 Zusammensetzung mit immunogenen mikroteilchen ATE501726T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR0117A AUPR011700A0 (en) 2000-09-14 2000-09-14 Composition comprising immunogenic virus sized particles (VSP)
AUPR4888A AUPR488801A0 (en) 2001-05-10 2001-05-10 Composition comprising immunogenic virus sized particles (vsp)
AUPR4962A AUPR496201A0 (en) 2001-05-14 2001-05-14 Composition comprising immunogenic virus sized particles (VSP)
PCT/AU2001/001160 WO2002022164A1 (en) 2000-09-14 2001-09-14 Composition comprising immunogenic microparticles

Publications (1)

Publication Number Publication Date
ATE501726T1 true ATE501726T1 (de) 2011-04-15

Family

ID=27158243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966829T ATE501726T1 (de) 2000-09-14 2001-09-14 Zusammensetzung mit immunogenen mikroteilchen

Country Status (15)

Country Link
US (3) US20040014708A1 (de)
EP (1) EP1326633B1 (de)
JP (1) JP5198712B2 (de)
KR (1) KR20030055262A (de)
CN (1) CN100446811C (de)
AT (1) ATE501726T1 (de)
AU (1) AUPR011700A0 (de)
CA (1) CA2422575C (de)
DE (1) DE60144240D1 (de)
DK (1) DK1326633T3 (de)
ES (1) ES2363735T3 (de)
IL (1) IL154913A0 (de)
NZ (2) NZ524843A (de)
PT (1) PT1326633E (de)
WO (1) WO2002022164A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
MXPA05012080A (es) * 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
WO2005053740A1 (ja) * 2003-12-02 2005-06-16 Bio Matrix Research Inc. 免疫増強剤およびこれを用いた強化抗原
WO2006012695A1 (en) * 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
US20090156480A1 (en) * 2005-08-25 2009-06-18 Mitsuru Akashi Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
WO2008150276A2 (en) * 2006-09-26 2008-12-11 The Board Of Regents Of The University Of Texas System Virus coated nanoparticles and uses thereof
BRPI1016133A2 (pt) 2009-04-01 2016-04-19 Univ Miami vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula.
US20120129199A1 (en) * 2009-05-19 2012-05-24 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
CN103282023B (zh) 2010-11-05 2018-09-21 诺瓦瓦克斯股份有限公司 狂犬病糖蛋白病毒样颗粒(vlp)
WO2012099805A2 (en) * 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2013052167A2 (en) * 2011-06-02 2013-04-11 The Regents Of The University Of California Membrane encapsulated nanoparticles and method of use
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
KR20170117450A (ko) 2015-02-18 2017-10-23 엔리벡스 테라퓨틱스 리미티드 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2016176041A1 (en) 2015-04-29 2016-11-03 The Regents Of The University Of California Detoxification using nanoparticles
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CN109200271B (zh) * 2018-11-14 2021-01-29 江南大学 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用
WO2020257315A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Multiple antigen protein displayed adjuvant systems
US20220273790A1 (en) * 2019-06-18 2022-09-01 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
CN110339350A (zh) * 2019-07-25 2019-10-18 广州中科蓝华生物科技有限公司 一种抗肿瘤的联合用药物组合物及其应用
AU2021319206A1 (en) * 2020-07-31 2023-03-02 The Board Of Trustees Of The Leland Stanford Junior University Vaccine compositions and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4035316A (en) * 1975-11-24 1977-07-12 California Institute Of Technology Cell specific, variable density, polymer microspheres
US4170685A (en) * 1976-03-29 1979-10-09 California Institute Of Technology Polyvinyl pyridine microspheres
US4157323A (en) * 1976-06-09 1979-06-05 California Institute Of Technology Metal containing polymeric functional microspheres
US4247434A (en) * 1978-12-29 1981-01-27 Lovelace Alan M Administrator Process for preparation of large-particle-size monodisperse
US4438239A (en) * 1981-03-30 1984-03-20 California Institute Of Technology Microsphere coated substrate containing reactive aldehyde groups
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4828984A (en) * 1986-04-11 1989-05-09 Flow Cytometry Standards Corporation Composition, synthesis and use of simulated cells
US6338853B1 (en) 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5219577A (en) * 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5665582A (en) * 1990-10-29 1997-09-09 Dekalb Genetics Corp. Isolation of biological materials
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996014855A1 (en) 1994-11-15 1996-05-23 Agracetus, Inc. Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
JPH10511957A (ja) 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
EP0840623B1 (de) * 1995-07-21 2007-07-18 Brown University Research Foundation Zusammensetzungen zur gentherapie die nukleinsäure-beladenen polymer-mikropartikeln enthalten
GB2330532A (en) * 1996-07-10 1999-04-28 Danbiosyst Uk Compositions suitable for delivery of genes to epithelial cells
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
EP0991403B1 (de) 1997-01-30 2003-04-02 Chiron Corporation Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
ES2248914T3 (es) 1997-08-29 2006-03-16 Corixa Corporation Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
US6001333A (en) 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
DE69921773D1 (de) 1998-01-16 2004-12-16 Univ Johns Hopkins Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
SE9800615D0 (sv) 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1107782B1 (de) 1998-09-01 2009-12-23 Merrion Research III Limited Orale impfstoff-zusammensetzung
DK1150918T3 (da) * 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
US7247310B1 (en) 1999-02-09 2007-07-24 Cell-Medicine, Inc. Tumor vaccines
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
AU4373499A (en) 1999-06-02 2000-12-28 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
EP1118331A1 (de) 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Verfahren zur Verstärkung der Präsentation exogener Antigene durch menschlische Antigen-präsentierende Zellen und opsonisierte Mikropartikelkomplexe zur Anwendung dieser Methode
EP1265598B1 (de) 2000-03-22 2006-08-02 The Secretary of State for Defence Arzneimittel zur verabreichung an schleimhäute
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2859909B1 (fr) 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
JP4772693B2 (ja) 2003-12-11 2011-09-14 ヴァックスデザイン・コーポレーション 免疫治療組成物、その製造方法及び使用方法
JP5806444B2 (ja) 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
WO2007100699A2 (en) 2006-02-24 2007-09-07 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
CN101472598A (zh) 2006-06-20 2009-07-01 Cmp医疗有限公司 包含壳多糖微粒的组合物及其医药用途
US8333972B2 (en) 2006-08-16 2012-12-18 Temple University Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
US20090202651A1 (en) 2006-08-28 2009-08-13 Moody Michael A Antigen specific fluorescent nanoparticles
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
US9107858B2 (en) 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
EP2250189A4 (de) 2008-02-26 2012-07-04 Univ California Gylcopeptide sowie verfahren zu ihrer herstellung und verwendung
CN102325546A (zh) 2009-01-20 2012-01-18 西北大学 用于诱导抗原-特异性耐受的组合物和方法

Also Published As

Publication number Publication date
NZ535851A (en) 2006-04-28
PT1326633E (pt) 2011-06-29
US20040014708A1 (en) 2004-01-22
CN100446811C (zh) 2008-12-31
CA2422575C (en) 2015-04-28
US8846026B2 (en) 2014-09-30
US20120082725A1 (en) 2012-04-05
CN1630531A (zh) 2005-06-22
IL154913A0 (en) 2003-10-31
WO2002022164A1 (en) 2002-03-21
AUPR011700A0 (en) 2000-10-05
US20100136043A1 (en) 2010-06-03
JP2004507566A (ja) 2004-03-11
EP1326633A1 (de) 2003-07-16
KR20030055262A (ko) 2003-07-02
DK1326633T3 (da) 2011-07-04
JP5198712B2 (ja) 2013-05-15
DE60144240D1 (de) 2011-04-28
US8287877B2 (en) 2012-10-16
NZ524843A (en) 2004-11-26
ES2363735T3 (es) 2011-08-12
EP1326633B1 (de) 2011-03-16
EP1326633A4 (de) 2006-05-24
CA2422575A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2005037190A3 (en) Multiplex vaccines
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
WO2004030608A3 (en) Nanoemulsion vaccines
TR200102739T2 (tr) Aşı
EP1594536A4 (de) Adjuvante influenza-vakzine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
PT2364724E (pt) Composição de vacina compreendendo um adjuvante de saponina
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE413888T1 (de) Salmonella vakzine
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2003053338A3 (en) Novel chimeric rev, tat, and nef antigens
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE60126490D1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
WO2002032455A3 (en) Vaccine
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
DK1204420T3 (da) Trehaloseproducerende prokaryotiske celler som vacciner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326633

Country of ref document: EP